Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Richard Dodel, Harald Hampel, Candan Depboylu, Suizhen Lin, Feng Gao, Sabine Schock, Steffi Jäckel, Xing Wei, Katharina Buerger, Christine Höft, Bernhard Hemmer, Hans Jürgen Möller, Martin Farlow, Wolfgang H. Oertel, Norbert Sommer, Yansheng Du

Research output: Contribution to journalArticle

141 Scopus citations


Naturally occurring antibodies directed against β-amyloid (Aβ) were detected in intravenous immunoglobulin preparations. After intravenous immunoglobulin treatment in patients with different neurological diseases, total Aβ and Aβ1-42 in the cerebrospinal fluid was reduced significantly compared with baseline values. In the serum, total Aβ levels increased after intravenous immunoglobulin treatment, whereas no significant change was observed in Aβ1-42 levels. Antibodies against Aβ were found to be increased in the serum and cerebrospinal fluid after intravenous immunoglobulin treatment. This study provides evidence that intravenous immunoglobulin or purified Aβ antibodies may modify Aβ and Aβ1-42 levels, suggesting potential utility as a therapy for Alzheimer disease.

Original languageEnglish (US)
Pages (from-to)253-256
Number of pages4
JournalAnnals of Neurology
Issue number2
StatePublished - Aug 5 2002


ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Dodel, R., Hampel, H., Depboylu, C., Lin, S., Gao, F., Schock, S., Jäckel, S., Wei, X., Buerger, K., Höft, C., Hemmer, B., Möller, H. J., Farlow, M., Oertel, W. H., Sommer, N., & Du, Y. (2002). Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease. Annals of Neurology, 52(2), 253-256.